AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30848259 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI + ALG‐6 (172 kcal sugar beverage with mixed SPI and alginate at pH 6)
Number of subjects: 12
Study 30848259 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI + ALG‐6
Number of subjects: 12
Study 30848259 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI + ALG‐7
Number of subjects: 12
Study 30848259 — intervention group
Group type: COMPARATOR
Intervention: CONT (122 kcal sugar beverage)
Number of subjects: 12
Study 29557854 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally-tailored demand creation activities (mass media, community mobilization, targeted service delivery)
Number of subjects: 10217
Study 29557854 — intervention group
Group type: COMPARATOR
Intervention: Control arms (no tailored demand creation)
Number of subjects: 10217
Study 29557854 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally-tailored demand creation activities
Number of subjects: 10217
Study 26863234 — intervention group
Group type: EXPERIMENTAL
Intervention: l-citrulline
Number of subjects: 41
Study 26863234 — intervention group
Group type: EXPERIMENTAL
Intervention: WBVT+l-citrulline
Number of subjects: 41
Study 26863234 — intervention group
Group type: COMPARATOR
Intervention: WBVT+Placebo
Number of subjects: 41
Study 24229467 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrothermally processed maize starch (HPMS)
Number of subjects: 8
Study 24229467 — intervention group
Group type: COMPARATOR
Intervention: Uncooked maize starch (UCMS)
Number of subjects: 8
Study 24229467 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (DEX)
Number of subjects: 8
Study 22828696 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic interlaminar epidural injections with or without steroids
Number of subjects: 17
Study 20429696 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 153
Study 20429696 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment (reference group)
Number of subjects: 153
Study 17505569 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 16153514 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation in patients with atrial fibrillation and echocardiographic risk factors
Number of subjects: 173
Study 16153514 — intervention group
Group type: COMPARATOR
Intervention: Control group (atrial fibrillation patients without echocardiographic risk factors)
Number of subjects: 173
Study 11773086 — intervention group
Group type: EXPERIMENTAL
Intervention: Precore mutant ratios at baseline in group 1 (persistent high viremia and ALT elevation after anti-HBe seroconversion)
Number of subjects: 53
Study 11773086 — intervention group
Group type: COMPARATOR
Intervention: Precore mutant ratios at baseline in group 2 (remission)
Number of subjects: 53
Study 11773086 — intervention group
Group type: EXPERIMENTAL
Intervention: Precore mutant ratios >50% at baseline
Number of subjects: 53
Study 11773086 — intervention group
Group type: COMPARATOR
Intervention: Precore mutant ratios <50% at baseline
Number of subjects: 53
Study 11773086 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of precore mutant ratios with ALT levels
Number of subjects: 53
Study 11773086 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of intervals from presentation to anti-HBe seroconversion with ALT and precore mutant ratios
Number of subjects: 53
Study 10549964 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg intramuscular pethidine
Number of subjects: 133
Study 10549964 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg intramuscular diamorphine
Number of subjects: 133
Study 10549964 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg intramuscular pethidine
Number of subjects: 133
Study 10549964 — intervention group
Group type: COMPARATOR
Intervention: 5 mg intramuscular diamorphine
Number of subjects: 133
Study 7796785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk
Number of subjects: 9
Study 7796785 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented low-fat milk
Number of subjects: 9
Study 7796785 — intervention group
Group type: COMPARATOR
Intervention: Lemonade (control)
Number of subjects: 9
Study 2347416 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and nandrolone decanoate
Number of subjects: 51
Study 2347416 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone (Control)
Number of subjects: 51
Study 2347416 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen and nandrolone decanoate (and Control)
Number of subjects: 51
Study 367136 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of isosorbide dinitrate
Number of subjects: 9
Study 367136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30381248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (100 mg)
Number of subjects: 24
Study 30381248 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine (40 mg)
Number of subjects: 24
Study 30381248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26888874 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of parenteral nutrition (n = 59)
Number of subjects: 121
Study 26888874 — intervention group
Group type: COMPARATOR
Intervention: Peripheral IV administration of parenteral nutrition (n = 61)
Number of subjects: 121
Study 25462646 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-family group therapy (MFGT) intervention (six sessions)
Number of subjects: 46
Study 25462646 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 46
Study 23562264 — intervention group
Group type: EXPERIMENTAL
Intervention: nalmefene 18 mg/day
Number of subjects: 718
Study 23562264 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 718
Study 21519049 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial plexus block (sympathectomy)
Number of subjects: 10
Study 21519049 — intervention group
Group type: COMPARATOR
Intervention: Non-blocked arm (control)
Number of subjects: 10
Study 19230711 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 3114
Study 19230711 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 3114
Study 16203059 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of pneumococcal conjugate vaccine (PCV)
Number of subjects: 0
Study 12771523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical treatment with interferon‐a2b (IFN‐a2b); administered weekly for 2 months, then twice a month for 4 months, and monthly for 6 months.
Number of subjects: 47
Study 12771523 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment); 10 patients.
Number of subjects: 47
Study 11879269 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychosocial intervention (six weekly cognitive/behavioral meetings)
Number of subjects: 89
Study 11879269 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychosocial intervention
Number of subjects: 89
Study 11879269 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual psychosocial care)
Number of subjects: 89
Study 9480241 — intervention group
Group type: EXPERIMENTAL
Intervention: Examined group (pH < 7.30)
Number of subjects: 64
Study 9480241 — intervention group
Group type: COMPARATOR
Intervention: Control group (pH = 7.30)
Number of subjects: 64
Study 7930245 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty of the left anterior descending coronary artery (Group IA, n = 9)
Number of subjects: 45
Study 7930245 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty of a major artery (Group IB, n = 11)
Number of subjects: 45
Study 7930245 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiography without coronary angioplasty (Group II, n = 12)
Number of subjects: 45
Study 7930245 — intervention group
Group type: COMPARATOR
Intervention: Right heart catheterization without angiography (Group III, n = 13)
Number of subjects: 45
Study 3079010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg three times daily
Number of subjects: 114
Study 3079010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg three times daily
Number of subjects: 114
Study 3079010 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg three times daily
Number of subjects: 114
Study 1944608 — intervention group
Group type: EXPERIMENTAL
Intervention: 1, 3, or 5 x 10(6) units of recombinant alpha‐interferon
Number of subjects: 10
Study 1944608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1944608 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 10(6) units of recombinant alpha‐interferon
Number of subjects: 10
Study 339448 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly continuation regimen of streptomycin plus isoniazid after 13 weeks of initial daily triple chemotherapy
Number of subjects: 272
Study 339448 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly continuation regimen of streptomycin plus isoniazid after 6 weeks of initial daily triple chemotherapy
Number of subjects: 272
Study 339448 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly regimen of streptomycin plus isoniazid after 13 weeks of initial daily triple chemotherapy
Number of subjects: 272
Study 339448 — intervention group
Group type: COMPARATOR
Intervention: 12 months of chemotherapy
Number of subjects: 272
Study 339448 — intervention group
Group type: COMPARATOR
Intervention: 18 months of chemotherapy
Number of subjects: 272
Study 31751908 — intervention group
Group type: EXPERIMENTAL
Intervention: Long sleep opportunity (time in bed: 9.5 h/night)
Number of subjects: 54
Study 31751908 — intervention group
Group type: COMPARATOR
Intervention: Short sleep opportunity (time in bed: 6.5 h/night)
Number of subjects: 54
Study 31046752 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention promoting clinical algorithms for caesarean decision-making (in-site training, audits, feedback, SMS reminders)
Number of subjects: 4174
Study 31046752 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 4174
Study 31046752 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 4174
Study 29052529 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced ART-adherence support
Number of subjects: 0
Study 29052529 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 26097987 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 26097987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24167993 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral endoscopic adenoidectomy
Number of subjects: 83
Study 24167993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adenoidectomy)
Number of subjects: 83
Study 20640848 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet gel (APG) applied after prosthesis implantation
Number of subjects: 40
Study 20640848 — intervention group
Group type: COMPARATOR
Intervention: Control group (no APG)
Number of subjects: 40
Study 20640848 — intervention group
Group type: EXPERIMENTAL
Intervention: APG group
Number of subjects: 40
Study 19813467 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of clarithromycin suspension (500 mg)
Number of subjects: 24
Study 19813467 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of clarithromycin suspension (500 mg)
Number of subjects: 24
Study 17541852 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment in females with poor metabolic status (PM)
Number of subjects: 55
Study 17541852 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment in males with poor metabolic status (PM)
Number of subjects: 55
Study 17541852 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment in females with extensive metabolic status (EM)
Number of subjects: 55
Study 17541852 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment in males with extensive metabolic status (EM)
Number of subjects: 55
Study 12786918 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide (9 mg/kg per day by mouth divided 3 times a day with food)
Number of subjects: 118
Study 12786918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 10925968 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 25-400 mg b.i.d.
Number of subjects: 11008
Study 10925968 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific NSAIDs (naproxen 500 mg b.i.d., diclofenac 50 or 75 mg b.i.d., ibuprofen 800 mg t.i.d.)
Number of subjects: 11008
Study 10925968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11008
Study 10925968 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100-400 mg b.i.d. (long-term open-label trial)
Number of subjects: 11008
Study 8642439 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine oil eicosapentaenoic acid (EPA) (0.3%) and docosahexaenoic acid (DHA) (0.2%) added to formula
Number of subjects: 0
Study 8642439 — intervention group
Group type: COMPARATOR
Intervention: Marine oil DHA (0.2%) with less EPA (0.06%) fed for a shorter interval
Number of subjects: 0
Study 8642439 — intervention group
Group type: EXPERIMENTAL
Intervention: AA (0.43%) and DHA (0.1%)
Number of subjects: 0
Study 1346505 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 400 mg daily
Number of subjects: 474
Study 1346505 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 800 mg daily
Number of subjects: 474
Study 1346505 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 1200 mg daily
Number of subjects: 474
Study 1346505 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (all doses)
Number of subjects: 474
Study 6593147 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride gel (5 min once weekly)
Number of subjects: 1286
Study 6593147 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-free dentifrice (twice daily)
Number of subjects: 1286
Study 31570028 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan-S with 200 mg oral mifepristone (study group)
Number of subjects: 127
Study 31570028 — intervention group
Group type: COMPARATOR
Intervention: Dilapan-S alone (control group)
Number of subjects: 127
Study 30728457 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (given prior to therapy with idarubicin and etoposide)
Number of subjects: 268
Study 30728457 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (given concurrently with idarubicin and etoposide)
Number of subjects: 268
Study 30728457 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (given after therapy with idarubicin and etoposide)
Number of subjects: 268
Study 30728457 — intervention group
Group type: COMPARATOR
Intervention: STANDARD (idarubicin, cytarabine, etoposide)
Number of subjects: 268
Study 30728457 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine-containing arms
Number of subjects: 268
Study 28407823 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified high-flow nasal cannula (HHFNC)
Number of subjects: 78
Study 28407823 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 78
Study 25313094 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine 3 g/day
Number of subjects: 36
Study 25313094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23964657 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 24
Study 23964657 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 24
Study 22281895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine isethionate
Number of subjects: 185
Study 22281895 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate
Number of subjects: 185
Study 22281895 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 185
Study 19012060 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal moisturizer (VM)
Number of subjects: 40
Study 17110281 — intervention group
Group type: EXPERIMENTAL
Intervention: TCH346 0.5 mg
Number of subjects: 301
Study 17110281 — intervention group
Group type: EXPERIMENTAL
Intervention: TCH346 2.5 mg
Number of subjects: 301
Study 17110281 — intervention group
Group type: EXPERIMENTAL
Intervention: TCH346 10 mg
Number of subjects: 301
Study 17110281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 17110281 — intervention group
Group type: EXPERIMENTAL
Intervention: TCH346 (all doses)
Number of subjects: 301
Study 15538621 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 7446
Study 15538621 — intervention group
Group type: COMPARATOR
Intervention: Open hernioplasty
Number of subjects: 7446
Study 15538621 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hernia repair
Number of subjects: 7446
Study 10981568 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam i.p. group
Number of subjects: 90
Study 10981568 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam i.v. group
Number of subjects: 90
Study 10981568 — intervention group
Group type: COMPARATOR
Intervention: Saline group
Number of subjects: 90
Study 9237082 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 hr of food deprivation and a stressor (difficult to solve anagrams)
Number of subjects: 56
Study 9237082 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect (anxiety, depression, and anger)
Number of subjects: 56
Study 9237082 — intervention group
Group type: EXPERIMENTAL
Intervention: Food deprivation
Number of subjects: 56
Study 9237082 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 56
Study 8414858 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm room (mean ambient temperature 25.7 degrees C)
Number of subjects: 32
Study 8414858 — intervention group
Group type: COMPARATOR
Intervention: Cool room (mean temperature 19.4 degrees C)
Number of subjects: 32
Study 2871667 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (100 mg oral dose, given 6 hours after symptom onset)
Number of subjects: 21
Study 2871667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2871667 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 21
Study 2871667 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol and Placebo
Number of subjects: 21
Study 31644731 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy for caregivers
Number of subjects: 69
Study 28520735 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone initiation
Number of subjects: 168
Study 26188189 — intervention group
Group type: EXPERIMENTAL
Intervention: GEC-TGF-β1
Number of subjects: 102
Study 26188189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 23739574 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX (0.5‐1.0 μg/kg load, 0.2‐0.6 μg×kg⁻¹×h⁻¹ for 24 hours)
Number of subjects: 90
Study 23739574 — intervention group
Group type: COMPARATOR
Intervention: Propofol (0.5‐2.0 mg/kg load, 1‐3 mg×kg⁻¹×h⁻¹ for 72 hours)
Number of subjects: 90
Study 23739574 — intervention group
Group type: COMPARATOR
Intervention: Pethidine and other temporary medication (group C)
Number of subjects: 90
Study 23739574 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX
Number of subjects: 90
Study 23739574 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 90
Study 23739574 — intervention group
Group type: COMPARATOR
Intervention: Group B (Propofol)
Number of subjects: 90
Study 23739574 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (DEX)
Number of subjects: 90
Study 23739574 — intervention group
Group type: COMPARATOR
Intervention: Group C (Pethidine)
Number of subjects: 90
Study 22051828 — intervention group
Group type: EXPERIMENTAL
Intervention: Linfonex™ 1000 mg
Number of subjects: 22
Study 22051828 — intervention group
Group type: COMPARATOR
Intervention: Cellcept™ 1000 mg
Number of subjects: 22
Study 19292423 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee arthroscopic partial meniscectomy
Number of subjects: 83
Study 16874422 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel sulphate patch test
Number of subjects: 93
Study 16874422 — intervention group
Group type: COMPARATOR
Intervention: Negative fragrance patch test
Number of subjects: 93
Study 11469295 — intervention group
Group type: EXPERIMENTAL
Intervention: KT‐308 alone
Number of subjects: 80
Study 11469295 — intervention group
Group type: EXPERIMENTAL
Intervention: KT‐308 with a single gutta‐percha cone (SCGP)
Number of subjects: 80
Study 11469295 — intervention group
Group type: EXPERIMENTAL
Intervention: ZUT alone
Number of subjects: 80
Study 11469295 — intervention group
Group type: EXPERIMENTAL
Intervention: ZUT with SCGP
Number of subjects: 80
Study 11469295 — intervention group
Group type: EXPERIMENTAL
Intervention: AH26 alone
Number of subjects: 80
Study 11469295 — intervention group
Group type: EXPERIMENTAL
Intervention: AH26 with SCGP
Number of subjects: 80
Study 11469295 — intervention group
Group type: COMPARATOR
Intervention: Positive control - no root canal filling
Number of subjects: 80
Study 11469295 — intervention group
Group type: COMPARATOR
Intervention: Negative control - no root canal filling, sealed with C&B Metabond cement
Number of subjects: 80
Study 9207576 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation with FSH and IUI
Number of subjects: 311
Study 9207576 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 311
Study 8094349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg every 8 h for 7 days)
Number of subjects: 30
Study 8094349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same regimen as Nifedipine)
Number of subjects: 30
Study 3322097 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.15 mg.kg‐1, 0.25 mg.kg‐1, 0.30 mg.kg‐1, 0.35 mg.kg‐1, 0.40 mg.kg‐1 (open study)
Number of subjects: 102
Study 3322097 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.2 mg.kg‐1 (double-blind study)
Number of subjects: 102
Study 3322097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind study)
Number of subjects: 102
Study 29775954 — intervention group
Group type: EXPERIMENTAL
Intervention: Target group with specific physical therapy techniques added to conventional protocol
Number of subjects: 30